Compensated Awareness Post View
Disclaimer
SKVI Management at a Glance
Skinvisible (SKVI) has assembled a team of seasoned professionals to protect and expand its patented technology family of polymer delivery vehicles called, Invisicare®. The executive management team has led Skinvisible to secure 14 granted patents with numerous patents pending using its Invisicare technology to produce innovative prescription dermatology and over-the-counter skincare products.
Skinvisible is led by Terry Howlett, President and Chief Executive Officer, who founded the company in 1998. With experience in venture capital financing, Howlett has a 30-year track record of entrepreneurial, business management, and market initialization experience. He drives and directs the company’s continual generation of new IP on dermatology and medical products formulated with Invisicare. Howlett has proven proficiency at guiding publicly traded start-up companies through the stages of capital formation, strategic planning, and business growth. His diversified background includes senior management, marketing, and sales positions with both established and start-up companies.
James A. Roszell, Ph.D. Chemist spearheads research and development of the company's patented technology, related polymer delivery vehicles, product formulations and compositions. A veteran doctoral chemist with over 35 years of experience in product formulation, experimental design, analysis and method validation, he joined Skinvisible in 1998. Dr. Roszell is a joint contributor to Skinvisible's Patent Number 6.756.059 and responsible for its four pending patents. Prior to joining Skinvisible, he worked as chemist for Supertech Products, Inc. where his responsibilities included ensuring compliance with OSHA, EPA and other standards and regulations, maintenance of quality control, research and development for new products. Dr. Roszell's background includes work in chemical, pharmaceutical, environmental and clinical laboratory arenas. His invaluable chemical and scientific expertise are key factors in Skinvisible's innovative technological achievements.
Doreen McMorran, Vice President - Business Development brings 20 years of experience in the medical and pharmaceutical industry to Skinvisible. With skills in strategic planning, sales and marketing, she devoted six years selling to international dermatology and skincare companies like Johnson & Johnson and Procter and Gamble. McMorran, who holds a Bachelor of Commerce (Cum Laude) degree, excelled in the pharmaceutical industry with Astra Pharma and held senior management level positions with several healthcare companies, focusing on business development, sales, marketing and operations.
Greg McCartney, Skinvisible Independent Director is chairman of the board and managing director of Taylor Butterfield & Worth Asset Management Corporation, a privately held equities firm. He has held senior executive and director positions in five North American Exchange listed companies and is presently president of a privately held investment firm, Aspenwood Holdings Corporation. He has over 20 years of capital markets experience and has been instrumental in supporting the financial requirements for several small to medium sized businesses over a broad market sector.
For more information, visit the company’s website at www.skinvisible.com
